Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care

Authors Carl Llor, Silvia Hernández, Anna Ribas, Carmen Álvarez, Josep Maria Cots, et al

Published 15 October 2008 Volume 2009:4 Pages 45—53

DOI https://doi.org/10.2147/COPD.S4177

Review by Single-blind

Peer reviewer comments 3

Carl Llor1, Silvia Hernández1, Anna Ribas2, Carmen Álvarez3, Josep Maria Cots4, Carolina Bayona5, Isabel González6, Marc Miravitlles7, BRAMOX Study Group

1Primary Care Centre Jaume I, Tarragona, Spain; 2Primary Care Centre Santa Eugènia de Berga, Spain; 3Primary Care Centre Manlleu, Spain; 4Primary Care Centre La Marina, Barcelona, Spain; 5Primary Care Centre Valls, Spain; 6Primary Care Centre Maragall, Barcelona, Spain; 7Pneumology Department. Institut Clínic del Tòrax (IDIBAPS), Hospital Clínic, Barcelona, CIBER de Enfermedades Respiratorias (CIBERES), Spain

Background: Amoxycillin/clavulanate is considered first-line treatment for ambulatory exacerbations of COPD. However, narrow-spectrum antibiotics may be as useful for mild to moderate patients.

Objective: To compare the clinical efficacy of amoxycillin versus amoxicyllin/clavulanate in exacerbations of COPD in primary care.

Methods: A randomized, double-blind, noninferiority clinical trial was carried out in eight primary care centers in Catalonia, Spain. Spirometrically-diagnosed patients older than 40 years with COPD, without criteria of hospitalization and Anthonisen’s types I or II exacerbations were included. The main outcome was clinical cure at the end of treatment (EOT) visit on day 10.

Results: A total of 137 patients were enrolled in the study (68 assigned to amoxycillin and 69 to amoxycillin/clavulanate). The mean forced expiratory flow in one second was 61.6% and the mean age was 71.4 years. At EOT, 92.8% of patients in the amoxycillin/clavulanate and 90.9% in the amoxycillin group were considered clinically cured, a statistically non-significant difference. Adverse effects were observed in 11 subjects, 3 in the amoxycillin group and 8 in the amoxycillin/clavulanate group, 2 of whom required a change in treatment.

Conclusions: Amoxycillin was at least as effective clinically and as safe as amoxycilin/clavulanate in the treatment of acute exacerbations of COPD in mild to moderate patients in primary care.

Keywords: exacerbation, chronic obstructive pulmonary disease, randomised controlled trial, amoxycillin, primary care, amoxycillin/clavulanate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOR phosphorylation

Sun ZH, Li QH, Zhang S, Chen J, Huang LL, Ren JH, Chang Y, Liang YC, Wu G

OncoTargets and Therapy 2015, 8:269-277

Published Date: 29 January 2015

Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units

Sundh J, Johansson G, Larsson K, Lindén A, Löfdahl CG, Janson C, Sandström T

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:173-183

Published Date: 22 January 2015

Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men

Gårevik N, Rane A, Björkhem-Bergman L, Ekström L

Substance Abuse and Rehabilitation 2014, 5:121-127

Published Date: 10 December 2014

In situ precipitation: a novel approach for preparation of iron-oxide magnetoliposomes

Xia S, Li P, Chen Q, Armah M, Ying X, Wu J, Lai J

International Journal of Nanomedicine 2014, 9:2607-2617

Published Date: 23 May 2014

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Multi-access drug delivery network and stability

Mitatha S, Moongfangklang N, Jalil MA, Suwanpayak N, Ali J, Yupapin PP

International Journal of Nanomedicine 2011, 6:1757-1764

Published Date: 23 August 2011

Cytomegalovirus infection presenting as a colonic mass in a patient with acquired immunodeficiency syndrome

Rajan DP, Jacob R, Rashid S, Vardaros M, Pigal A, Gebre W, Rizvon K, Subramani K, Takeshige U, Mustacchia P

International Medical Case Reports Journal 2011, 4:55-58

Published Date: 22 July 2011

Hepatitis C virus infection and risk of cancer: a population-based cohort study

Lars Haukali Omland, Dora Körmendiné Farkas, Peter Jepsen, et al

Clinical Epidemiology 2010, 2:179-186

Published Date: 24 June 2010

Corrigendum

Dove Medical Press Editorial

Vascular Health and Risk Management 2009, 5:273-274

Published Date: 18 March 2009